Carlyle Group Amends Adicet Bio Stake, Ownership Update Filed

TL;DR

**Carlyle Group just updated its Adicet Bio ownership, watch for potential stock movement.**

AI Summary

Carlyle Group Inc. and its affiliates, including Abingworth Bioventures 8 LP, filed an amended Schedule 13D/A on February 7, 2024, indicating a change in their beneficial ownership of Adicet Bio, Inc. common stock. This amendment, triggered by an event on January 25, 2024, updates their previous filings regarding their stake in the pharmaceutical company. This matters to investors as significant changes in institutional ownership can signal shifts in confidence or strategic intent, potentially influencing stock price and future corporate actions for Adicet Bio.

Why It Matters

Changes in major institutional holdings like Carlyle's can signal shifts in investor confidence or strategic direction for Adicet Bio, potentially impacting its stock valuation.

Risk Assessment

Risk Level: medium — Changes in major investor holdings can introduce uncertainty regarding future company direction or stock performance.

Analyst Insight

Investors should monitor subsequent filings for specific changes in ownership percentages or intentions, as this filing only indicates an update occurred, not the details of the change itself. This could be a precursor to further buying, selling, or strategic involvement.

Key Players & Entities

• Carlyle Group Inc. (company) — filing person, investment firm
• Adicet Bio, Inc. (company) — subject company, pharmaceutical preparations
• Abingworth Bioventures 8 LP (company) — group member, investment entity
• Jeffrey Ferguson (person) — person authorized to receive notices for Carlyle Group
• January 25, 2024 (date) — date of event requiring the filing
• $0.0001 (dollar_amount) — par value per share of Adicet Bio Common Stock

FAQ

Key Financial Figures

• $0.0001 — me of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securiti
• $2.40 — from the Issuer at a purchase price of $2.40 per share (the January 2024 PIPE). Abin

Filing Documents

• d682129dsc13da.htm (SC 13D/A) — 172KB
• d682129dex992.htm (EX-99.2) — 12KB
• 0001193125-24-026734.txt ( ) — 186KB

of the Schedule 13D is hereby amended and supplemented as follows

Item 3 of the Schedule 13D is hereby amended and supplemented as follows: On January 25, 2024, Abingworth Bioventures 8 LP purchased 833,333 shares of Common Stock in a private placement from the Issuer at a purchase price of $2.40 per share (the January 2024 PIPE). Abingworth Bioventures 8 LP purchased the Common Stock with its investment capital. Item4. Purpose of Transaction.

of the Schedule 13D is hereby amended and supplemented as follows

Item 4 of the Schedule 13D is hereby amended and supplemented as follows: January 2024 PIPE

above

Item 3 above summarizes the January 2024 PIPE and is incorporated herein by reference. Item5. Interest in Securities of the Issuer.

of the Schedule 13D is hereby amended and restated in its entirety as follows

Item 5 of the Schedule 13D is hereby amended and restated in its entirety as follows: (a) (b) The following sets forth, as of the date of this Schedule 13D, the aggregate number of shares of Common Stock and percentage of Common Stock beneficially owned by each of the Reporting Persons, as well as the number of shares of Common Stock as to which each Reporting Person has the sole power to vote or to direct the vote, shared power to vote or to direct the vote, sole power to dispose or to direct the disposition of, or shared power to dispose or to direct the disposition of, as of the date hereof, based on 75,487,588 shares of Common Stock outstanding following the closing of the January 2024 PIPE, as disclosed in the Issuers prospectus supplement filed with the Securities and Exchange Commission on January 24, 2024. Reporting Person Amount beneficially owned Percent of class Sole power to vote or to direct the vote Shared power to vote or to direct the vote Sole power to dispose or to direct the disposition Shared power to dispose or to direct the disposition The Carlyle Group Inc. 3,060,292 4.1 % 0 3,060,292 0 3,060,292 Carlyle Holdings I GP Inc. 3,060,292 4.1 % 0 3,060,292 0 3,060,292 Carlyle Holdings I GP Sub L.L.C. 3,060,292 4.1 % 0 3,060,292 0 3,060,292 Carlyle Holdings I L.P. 3,060,292 4.1 % 0 3,060,292 0 3,060,292 CG Subsidiary Holdings L.L.C. 3,060,292 4.1 % 0 3,060,292 0 3,060,292 TC Group, L.L.C. 3,060,292 4.1 % 0 3,060,292 0 3,060,292 Carlyle Investment Management L.L.C. 3,060,292 4.1 % 0 3,060,292 0 3,060,292 Carlyle Genesis UK LLC 3,060,292 4.1 % 0 3,060,292 0 3,060,292 Abingworth LLP 3,060,292 4.1 % 0 3,060,292 0 3,060,292 Abingworth Bioventures 8 LP 3,060,292 4.1 % 0 3,060,292 0 3,060,292 The shares of Common Stock reported herein include (i) 2,986,292 shares of Common Stock held of record by Ab

of the Schedule 13D is hereby amended and supplemented as follows

Item 7 of the Schedule 13D is hereby amended and supplemented as follows: Exhibit Number Description 1 Joint Filing Agreement (previously filed) 2 Power of Attorney.

SIGNATURES

SIGNATURES After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Date : February 7, 2024 The Carlyle Group Inc. By: /s/ Anne Frederick, attorney-in-fact Name: John C. Redett Title: Chief Financial Officer Carlyle Holdings I GP Inc. By: /s/ Anne Frederick, attorney-in-fact Name: John C. Redett Title: Managing Director and Chief Financial Officer Carlyle Holdings I GP Sub L.L.C. By: Carlyle Holdings I GP Inc., its sole member By: /s/ Anne Frederick, attorney-in-fact Name: John C. Redett Title: Managing Director and Chief Financial Officer Carlyle Holdings I L.P. By: /s/ Anne Frederick, attorney-in-fact Name: John C. Redett Title: Managing Director CG Subsidiary Holdings L.L.C. By: /s/ Anne Frederick, attorney-in-fact Name: John C. Redett Title: Managing Director TC Group, L.L.C. By: /s/ Anne Frederick, attorney-in-fact Name: John C. Redett Title: Managing Director Carlyle Investment Management L.L.C. By: /s/ Anne Frederick, attorney-in-fact Name: John C. Redett Title: Chief Financial Officer Carlyle Genesis UK LLC By: Carlyle Investment Management L.L.C., its sole member By: /s/ Anne Frederick, attorney-in-fact Name: John C. Redett Title: Chief Financial Officer Abingworth LLP By: /s/ John Heard Name: John Heard Title: Authorized Signatory Abingworth Bioventures 8 LP By: /s/ John Heard Name: John Heard Title: Authorized Signatory

View Full Filing

View this SC 13D/A filing on SEC EDGAR